- |||||||||| Review, Journal: A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo. (Pubmed Central) - Aug 1, 2024
Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.
- |||||||||| Journal: Network-Based Drug Repurposing and Genomic Analysis to Unveil Potential Therapeutics for Monkeypox Virus. (Pubmed Central) - Jul 31, 2024
In addition, the pharmacophore-based screening identified a molecule that is comparable to Baricitinib and has the potential to be effective against MPXV. The findings of the study suggest that ZINC22060520 is a promising medication for treating MPXV infection and proposes these medications as potential options for additional experimental and clinical assessment in the battle against MPXV.
- |||||||||| Humira (adalimumab) / AbbVie
PERSONALIZED IMMUNOMODULATORY DRUG REPURPOSING IN MUCOPOLYSACCHARIDOSES (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_494; The results will be integrated into the tool to improve its performance. So far, our tool can be used for paediatric and adult patients with MPS I, II, III, IV, VI, VII and IX and covers four immunomodulators.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Colonic Mucormycosis in Fistulizing Crohn's Disease. (Pubmed Central) - Jul 29, 2024 We present a case of a middle-aged female with perianal Crohn's disease on adalimumab who developed colonic mucormycosis causing a flare in her disease activity. This patient highlights the need to increase awareness about fungal infections as a cause of disease flare in inflammatory bowel disease.
- |||||||||| Bimzelx (bimekizumab) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Review, Journal: Hidradenitis Suppurativa: New Targets and Emerging Treatments. (Pubmed Central) - Jul 27, 2024 Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics-adalimumab, secukinumab, and bimekizumab-have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.
- |||||||||| Humira (adalimumab) / AbbVie
Journal, Immunomodulating: A case of AZOOR under immunomodulatory treatment. (Pubmed Central) - Jul 27, 2024 Complete diagnostic work-up is important to rule out other etiologies. Due to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- |||||||||| Review, Journal: Management of JIA associated uveitis. (Pubmed Central) - Jul 26, 2024
Current international recommendations advise a step-wise approach, starting with methotrexate and moving on to adalimumab if methotrexate alone is not sufficient to control the disease. If the uveitis remains active despite standard treatment other therapeutic options may be considered including anti-IL6 or other anti-TNF agents such as infliximab, although the evidence for these agents is limited.
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Retrospective data, Review, Journal: Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety. (Pubmed Central) - Jul 26, 2024 Upadacitinib exhibited satisfactory efficacy in treating axial spondyloarthritis, reducing disease activity and significantly enhancing patients' physical function, emotional well-being, and social engagement. This meta-analysis offers robust evidence supporting upadacitinib as a new treatment for axial spondyloarthritis patients.
- |||||||||| Bimzelx (bimekizumab) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Review, Journal: Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. (Pubmed Central) - Jul 23, 2024 The three approved biologics for treating HS include adalimumab, secukinumab and bimekizumab; the benefits and concerns of biologics in everyday clinical practice are detailed. In summary, this review serves as a HS management guide for GPs, with a particular focus on the biologic treatment landscape.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Biologic treatment sequences in moderate-to-severe psoriasis. (Pubmed Central) - Jul 23, 2024 However, existing trials are limited, and more well-designed trials are necessary to clarify the role of TDM in adalimumab treatment. This study demonstrates an increased uptake of more novel biologics as they become available, due to improved safety profiles and clinical outcomes.
- |||||||||| Journal, Adverse events, Real-world evidence, Real-world: Safety of TNF-? inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database. (Pubmed Central) - Jul 19, 2024
The analysis indicates that infliximab is associated with 60 unique positive ADEs, including Hodgkin's disease, metastatic neoplasm, and non-Hodgkin's lymphoma; therefore, these patients should use infliximab with greater caution. Similarly, certolizumab should be used with increased caution in pregnant and postpartum women.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Isolated cardiac sarcoidosis presenting as transient ischemic attack. (Pubmed Central) - Jul 18, 2024 In conclusion, this case highlights the need to consider CS as a potential cause of cerebrovascular ischemic events in patients with few stroke risk factors but findings indicative of cardiac disease. It is essential to further explore the mechanisms behind these events and develop treatments that target their causes in this patient population.
- |||||||||| tofacitinib / Generic mfg.
Journal: A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report. (Pubmed Central) - Jul 17, 2024 Subsequent use of adalimumab and secukinumab resulted in worsening skin rash, prompting a switch to tofacitinib, leading to a remarkable improvement in pustular eruptions after 20 days of treatment. This case demonstrates successful application of tofacitinib in treating severe keratoderma blennorrhagicum refractory to conventional DMARDs and biologics, offering insights into JAK inhibition for challenging rheumatic diseases with skin involvement.
- |||||||||| Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Plasma Cytokines for the Prediction of the Effectiveness of TNF? Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. (Pubmed Central) - Jul 13, 2024 The baseline levels of VEGF, sCD40L, and ICAM1, as well as IL20, could serve as potential predictors of treatment effectiveness using TNFa inhibitors. However, this hypothesis requires confirmation with a larger patient population.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: A case of juvenile-onset ankylosing spondylitis effectively treated with tumour necrosis factor-alpha inhibitor agents. (Pubmed Central) - Jul 8, 2024 The bath ankylosing spondylitis disease activity index (BASDAI) value was 8.0 at the time of induction and 3.1 at 6?months after the introduction of adalimumab (at a dose of 40?mg)...The BASDAI value was 2.6 at 6?months, 2.7 at 1?year, and 1.8 at 1.5?years after the introduction of infliximab, indicating that the patient had progressed well without any adverse events...TNF inhibitors were effective in treating juvenile ankylosing spondylitis in the present case without any adverse events. This case is notable because juvenile onset ankylosing spondylitis is one of the reasons for severe lumbago since childhood and because TNF inhibitors were administered promptly after diagnosis.
|